Revolutionary Biological Dynamics Case Study Impacts Early-Stage Pancreatic Cancer Detection

Biodynamic Technologies is delighted to announce a pioneering breakthrough in the early detection of pancreatic pre-cancer lesion – as detailed in their newly published case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy”, in Frontiers in Oncology.

This achievement comes from the use of their exosome liquid biopsy assay, ExoVitaTM Pancreas – providing revolutionary insight into the earlier detection of pancreatic ductal adenocarcinoma (PDAC).

Pancreatic cancer is devastatingly fatal and currently stands as the third-leading cause of cancer-related death in the United States. Unfortunately, it often presents itself in late stages, leading to limited treatment options and a dire 5-year survival rate of just 12.5%.

This is why the emergence of the ExoVita Pancreas for early-stage PDAC detection is so exciting; boasting high sensitivity and specificity, it has the potential to drastically improve patient survival outcomes. Diagnosed and treated early, pancreatic cancer no longer has to be a death sentence.

This latest case report demonstrates the power of our ExoVita Pancreas technology in detecting exosomes from an early-stage lesion, which carries a high risk of rapidly becoming malignant. By being able to detect this precursor to cancer even before traditional diagnostics can detect any symptoms, our assay could be used to make a diagnosis at much earlier stages than ever before, greatly increasing the chances of a positive patient outcome.

Harmeet Dhani, M.D., M.Sc., Medical Director of Biological Dynamics, believes this clinical evidence shows the potential for our revolutionary assessment technique to bring about a whole new standard in cancer diagnosis and treatment.

A 60-year-old healthy, non-Hispanic white male was diagnosed with acute pancreatitis and underwent an extensive array of tests and procedures for ten months without any indication of pancreatic lesions or concerns. Fortunately, ExoVita Pancreas assay revealed a “high likelihood of PDAC”.

Further pathologic testing revealed the presence of high-grade intraductal papillary mucinous neoplasm (IPMN), in line with the ExoVita Pancreas results. To add to the good news, the patient underwent a post-operative ExoVita Pancreas signature test, which came back with no detected biomarkers, indicating a successful surgery and a return to a disease-free life.

By adding ExoVita Pancreas to the “watch-and-wait” approach, physicians can now more confidently direct optimal patient treatment options for both high and low-risk IPMN patients. Rather than relying on invasive, frequent scans and chronic symptom monitoring, ExoVita Pancreas can help ensure patients get the best care possible.

Biological Dynamics’ ExoVerita exosome isolation platform is paving the way for earlier cancer detection through cutting-edge biomarkers and technology. The ExoVita Pancreas test, which isolates exosomes found in patient blood samples, has already shown high sensitivity and specificity in detecting cancer at stages I and II, but now has the potential to detect precancerous lesions as well. For those at higher risk, this could mean catching cancer in its earliest stages, and drastically improving survival rates.

About Biological Dynamics

Biological Dynamics is a leader in disease detection technology, working to improve global health outcomes through the power of early detection. Leveraging their proprietary ExoVerita™ exosome-isolation platform, the company is undertaking the ExoLuminate study to demonstrate the effectiveness of their ExoVita™ Pancreas assay for early-stage detection of pancreatic cancer.

The assay is a lab-developed test (LDT) and is validated and performed in their CAP and CLIA-certified clinical laboratory in San Diego. With these innovative approaches, Biological Dynamics is dedicated to enabling better health decisions and outcomes for patients and physicians everywhere.

Leave a Comment